US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Acura Pharmaceuticals, Inc.

0.0005

0.0000

Volume:- -

Turnover:- -

Market Cap:33.25K

PE:-0.02

High:0.0005

Open:0.0005

Low:0.0005

Close:0.0005

52wk High:0.1780

52wk Low:0.0001

Shares:66.50M

Float Shares:9.99M

Volume Ratio:0.01

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0200

EPS(LYR):-0.0200

ROE:15.24%

ROA:-58.46%

PB:0.19

PE(LYR):-0.02

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Acura Pharmaceuticals Amends Secured Loan Agreement to Increase Principal to $9.59 Million

Acura Pharmaceuticals Amends Loan Agreement to Secure Up to $9.29 Million Financing

Acura Pharmaceuticals Delays Filing Multiple Financial Reports

Acura Pharmaceuticals Amends Secured Loan Agreement to Increase Principal to $8.99 Million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ACUR"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACUR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACUR\",,,,,undefined,":{"symbol":"ACUR","market":"US","secType":"STK","nameCN":"Acura Pharmaceuticals, Inc.","latestPrice":0.0005,"timestamp":1770411600000,"preClose":0.0005,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":9990324,"shares":66499283,"eps":-0.02,"marketStatus":"Market Closed","change":0,"latestTime":"02-06 16:00:00 EST Delay","open":0.0005,"high":0.0005,"low":0.0005,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.02,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"EXPERT","adjPreClose":0.0005,"volumeRatio":0.005010018785065434},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACUR\",,,,,undefined,":{"symbol":"ACUR","floatShares":9990324,"roa":"-58.46%","roe":"15.24%","lyrEps":-0.02,"volumeRatio":0.005010018785065434,"shares":66499283,"dividePrice":0,"high":0.0005,"amplitude":0,"preClose":0.0005,"low":0.0005,"week52Low":0.0001,"pbRate":"0.19","psRate":"0.02","week52High":0.178,"institutionHeld":0,"latestPrice":0.0005,"eps":-0.02,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.02,"open":0.0005,"prevYearClose":0.0005,"prevWeekClose":0.0005,"prevMonthClose":0.0005,"prevQuarterClose":0.0005,"fiveDayClose":0.0005,"twentyDayClose":0.0005,"sixtyDayClose":0.0005},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACUR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2021-05-17","symbol":"ACUR","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1621224000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2021-03-31","symbol":"ACUR","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1617163200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2020-11-16","symbol":"ACUR","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1605502800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2020-06-29","symbol":"ACUR","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1593403200000,"reportTimeType":"post","actualEps":null},{"date":"2020-06-15","symbol":"ACUR","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1592251200000,"name":null,"time":"Post Market","dateTimestamp":1592193600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACUR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ACUR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACUR\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2605314902","title":"Acura Pharmaceuticals Amends Secured Loan Agreement to Increase Principal to $9.59 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2605314902","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605314902?lang=en_us&edition=fundamental","pubTime":"2026-01-21 05:17","pubTimestamp":1768943824,"startTime":"0","endTime":"0","summary":"Acura Pharmaceuticals Inc. has amended its secured promissory note with Abuse Deterrent Pharma, LLC, increasing the aggregate principal amount of the loan facility. The original note, dated November 10, 2022, was for $2,319,279. Through a series of additional loans, the total principal will rise incrementally to $9,594,279 by January 16, 2026. The amendment details specific additional loan disbursements, each in the amount of $100,000, scheduled periodically between July 2025 and January 2026. The agreement was executed by Robert A. Seiser, Senior Vice President and CFO of Acura Pharmaceuticals Inc.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acura Pharmaceuticals Inc. published the original content used to generate this news brief ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL75pXqR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACUR","BK4007"],"gpt_icon":0},{"id":"2595738787","title":"Acura Pharmaceuticals Amends Loan Agreement to Secure Up to $9.29 Million Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2595738787","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595738787?lang=en_us&edition=fundamental","pubTime":"2025-12-29 20:31","pubTimestamp":1767011476,"startTime":"0","endTime":"0","summary":"Acura Pharmaceuticals Inc. has amended its existing secured promissory note with Abuse Deterrent Pharma, LLC, expanding the total principal amount available under the agreement. The original note, dated November 10, 2022, had a principal of $2,319,279. Subsequent amendments have added a series of additional loans, bringing the aggregated principal to $9,294,279 as of December 12, 2025. The amendment details the schedule of new loans, with individual disbursements of $100,000 each, extending through December 2025. The agreement was executed by Robert A. Seiser, Senior Vice President and CFO of Acura Pharmaceuticals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acura Pharmaceuticals Inc. published the original content used to generate ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDL2XDd1M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACUR","BK4007"],"gpt_icon":0},{"id":"2585128608","title":"Acura Pharmaceuticals Delays Filing Multiple Financial Reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2585128608","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585128608?lang=en_us&edition=fundamental","pubTime":"2025-11-22 02:46","pubTimestamp":1763750817,"startTime":"0","endTime":"0","summary":"Acura Pharmaceuticals Inc. has disclosed delays in filing its financial reports, including quarterly reports for the periods ending March 31, June 30, and September 30 for the years 2022, 2023, and 2024, as well as annual reports for the years ended December 31, 2022, 2023, and 2024. The company cited that the reports, including Forms 10-Q and 10-K, could not be filed on time without unreasonable effort or expense.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acura Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 21, 2025, and is solely responsible for the i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL6x8h2Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACUR","BK4007"],"gpt_icon":0},{"id":"2577337590","title":"Acura Pharmaceuticals Amends Secured Loan Agreement to Increase Principal to $8.99 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2577337590","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577337590?lang=en_us&edition=fundamental","pubTime":"2025-10-24 19:01","pubTimestamp":1761303679,"startTime":"0","endTime":"0","summary":"Acura Pharmaceuticals Inc. has amended its secured promissory note agreement with Abuse Deterrent Pharma, LLC. The updated loan schedule, dated October 23, 2025, reflects a series of additional loans made to Acura Pharmaceuticals since the original note was issued on November 10, 2022. The amendment documents a progression of individual loans, with principal amounts ranging from $100,000 to $125,000, extending through October 23, 2025. As a result of these additional loans, the aggregated principal under the agreement has increased to $8,994,279. The amendment was signed by Robert A. Seiser, Senior Vice President and CFO of Acura Pharmaceuticals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acura Pharmaceuticals Inc. published the or","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDL2CZt9h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACUR","BK4007"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ACUR\",params:#limit:6,delay:false,,,undefined,":[]}}